Formula I Heterocyclic Compounds Overcoming Plasmodium falciparum Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for new therapeutic agents with novel mechanisms of action to treat malaria, particularly due to emerging resistance to current treatments like artemisinins-based combination therapies and the high incidence of malaria, especially in regions like sub-Saharan Africa where Plasmodium falciparum infections are prevalent.
Innovation Solution
Development of novel compounds of Formula (I) or their pharmaceutically acceptable salts, which include specific heterocyclic structures such as imidazole, pyrazole, thiazole, and tetrazole derivatives, for use in treating parasitic protozoal infections, including malaria caused by Plasmodium falciparum, by administering a pharmaceutically effective amount to address the resistance issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If artemisinins-based combination therapies are used to treat malaria, then treatment effectiveness is improved, but drug resistance emerges over time
Solution Approach 1:
The patent applies parameter changes by developing compounds with modified chemical structures (Formula I with varying R1-R4 substituents and heterocyclic rings) that alter the molecular parameters of antimalarial agents. This structural modification enables the compounds to interact with different parasite targets, overcoming resistance mechanisms that have developed against conventional artemisinin-based therapies while maintaining treatment effectiveness.
Solution Approach 2:
The patent employs composite materials by creating hybrid molecular structures that combine different functional moieties - the core structure of Formula I is复合 with various heterocyclic rings (imidazole, pyrazole, thiazole, isothiazole, oxazole, isoxazole, triazole, or tetrazole) and substituent groups. This composite approach generates novel antimalarial compounds with enhanced activity and reduced cross-resistance compared to single-structure therapies.
2Adaptability or versatility
If new therapeutic agents with novel mechanisms of action are developed, then resistance issues are overcome, but drug development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the antimalarial compound into distinct functional segments: the core structure of Formula I, the heterocyclic ring system, and various substituent groups (R1-R4). This modular segmentation allows systematic optimization of each component's contribution to antimalarial activity, facilitating rational drug design and reducing overall development complexity despite the novel mechanism of action.
Solution Approach 2:
The patent employs universality by designing a versatile core structure (Formula I) that can accommodate multiple different heterocyclic rings and substituent variations. This multi-functional platform enables a single lead compound to be optimized for different therapeutic indications and resistance profiles, reducing the need to develop entirely separate drug candidates for different scenarios.
Data Source
AI summary
The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding compositions, and methods and/or uses in therapy, for example in the treatment of parasitic infections such as malaria, in particular infection by Plasmodium falciparum.